Page last updated: 2024-11-04

diatrizoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2140
CHEMBL ID1201220
CHEBI ID53691
SCHEMBL ID8508
MeSH IDM0067051

Synonyms (135)

Synonym
amidotrizoic acid
urografin acid
amidotrizoate
benzoic acid,5-bis(acetylamino)-2,4,6-triiodo-
benzoic acid,5-diacetamido-2,4,6-triiodo-
g 2-75
nsc-262168
odiston
2,6-triiodo-3,5-diacetamidobenzoic acid
117-96-4
wln: 1vmr bi di fi cvq emv1
s 17
diatriazoate
nsc262168
diat
diatrizoesaeure
3,4,6-triiodobenzoic acid
brn 2225144
acidum diacetylaminotrijodbenzoicum
diat [german]
benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo-
urotrast
acide amidotrizoique
amidotrzoique (acide)
triombrin [russian]
nsc 262168
diatrizoesaure [german]
benzoic acid, 3,5-diacetamido-2,4,6-triiodo-
hsdb 4042
acidum amidotrizoicum
einecs 204-223-6
urografic acid, sodium salt
gastrografin
vascoray
ml 216
triombrin
methalamic acid
win 8308-3
renografin 76
3,5-bis(acetylamino)-2,4,6-triiodobenzoic acid
sodium (diacetyldiamine)triiodobenzoate
diatrizoate
amidotrizoate (*sodium salt*)
(diacetyldiamine)triiodobenzoate
diatrizoic acid
3, 5-diacetamido-2,4,6-triiodobenzoic acid, sodium salt
3,5-diacetamido-2,4,6-triiodo-benzoic acid
diatrizoate sodium salt
hypaque 50
nsc61815
benzoic acid, 3,5-diacetamido-2,4, 6-triiodo-, sodium salt
diatrizoic acid dihydrate, meets usp testing specifications
urogranoic acid
amidotrizoic acid (anhydrous)
3,5-diacetamido-2,4,6-triiodobenzoic acid
2,4,6-triiodo-3,5-diacetamidobenzoic acid
diatrizoic acid (anhydrous)
DB00271
amidotrizoic acid (jp17)
diatrizoic acid (usp)
D02240
NCGC00021123-01
AC-4695
HMS2094A11
AKOS001073646
CHEBI:53691 ,
diatrizoesaure
3,5-bis(acetamido)-2,4,6-triiodobenzoic acid
3,5-di(acetamido)-2,4,6-triiodobenzoic acid
D1462
urothrast
diatrizoic acid [usan:usp]
unii-5uvc90j1lk
5uvc90j1lk ,
ec 204-223-6
dtxsid0044521 ,
cas-117-96-4
tox21_301929
dtxcid8024521
NCGC00255848-01
amidotrizoic acid, anhydrous
acidum amidotrizoicum, anhydrous
CHEMBL1201220
nsc760390
pharmakon1600-01505777
nsc-760390
S4563
FT-0624622
acidum amidotrizoicum [who-ip latin]
acidum amidotrizoicum, anhydrous [who-ip latin]
amidotrizoic acid [who-dd]
diatrizoic acid [mi]
amidotrizoic acid, anhydrous [who-ip]
diatrizoic acid [usp monograph]
amidotrizoic acid [jan]
diatrizoic acid [ii]
amidotrizoic acid [who-ip]
diatrizoic acid [hsdb]
diatrizoate [vandf]
diatrizoic acid [usp-rs]
3,5-bis-acetamido-2,4,6-triiodobenzoic acid
diatrizoic acid [usan]
amidotrizoic acid [mart.]
CCG-213547
SCHEMBL8508
AB00979425-01
3,5-diacetylamino-2,4,6-triiodobenzoic acid
3,5-bis(acetylamino)-2,4,6-triiodobenzoic acid; diatrizoic acid
bdbm62875
cid_8566
3,5-diacetamido-2,4,6-tris(iodanyl)benzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
3,5-diacetamido-2,4,6-triiodo-benzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
HY-B0926
AB00979425_02
mfcd00069960
amidotrizoic acid;diatrizoate
J-003688
amidotrizoic acid, analytical standard
amidotrizoic acid dihydrate, european pharmacopoeia (ep) reference standard
diatrizoic acid, united states pharmacopeia (usp) reference standard
AS-68015
amidotrizoic acid for system suitability, european pharmacopoeia (ep) reference standard
SBI-0206932.P001
Z56886396
Q411511
diatrizoic acid,(s)
diatrizoic-acid
3,5-diacetamido-2,4,6-triiodobenzoic acid; diatrizoic acid dehydrate;diatrizoic acid dihydrate
A871406
D89865
EN300-00176
diatrizoic acid (usp-rs)
diatrizoic acid (ii)
diatrizoic acid (usp monograph)
amidotrizoic acid (mart.)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The relation between ionic composition and cardiotoxicity of two dimers, iocarmate and iozomate, was investigated by selective injection into the left and right coronary arteries, Least toxic reactions developed at a sodium concentration of 263 to 315 mmol/l for sodium-meglumine iocarmate and 271 to 379 mmol/l for sodium-meglumine iozomate."( Ionic composition and cardiotoxicity of dimeric contrast media at injection into the coronary arteries of rabbits.
Carter, AM; Olin, T, 1976
)
0.26
" This suggests that occult vascular lesions may have been present in the allograft which were exacerbated when exposed to the irritant vascular effects of contrast media, producing a mild, reversible toxic nephritis."( Adverse effects of meglumine diatrizoate on renal function in the early post-transplant period.
Etheredge, EE; Hill, G; Light, JA; Perloff, LJ; Spees, EK, 1975
)
0.25
" Therefore, the non-ionic and slightly hyperosmolaric iohexol may be less toxic to the kidneys than the ionic and hypertonic diatrizoate."( [Comparative study on nephrotoxicity of ionic and non-ionic contrast agents for drip infused urography].
Harada, T; Miyagata, S; Nishizawa, O; Noto, H; Shimoda, N; Sugaya, K; Suzuki, T; Tsuchida, S, 1992
)
0.28
" Our data suggest that the nonionic low-osmolal radiocontrast medium iopamidol is less toxic to tubules than the ionic high-osmolal medium diatrizoate and that the brush-border enzymes AAP and gamma-GT are sensitive markers for this toxicity."( Tubular nephrotoxicity after intravenous urography with ionic high-osmolal and nonionic low-osmolal contrast media in patients with chronic renal insufficiency.
Arrigo, G; Bernasconi, P; Cavaliere, G; D'Amico, G; Dellafiore, L; Schiavina, G; Vergnaghi, D, 1987
)
0.27
" Recent experiments have demonstrated that sodium diatrizoate, a common ionic radiocontrast agent, is moderately toxic to proximal tubule cells in vitro, and that this toxicity is enhanced by hypoxia."( Comparison of the toxicity of the radiocontrast agents, iopamidol and diatrizoate, to rabbit renal proximal tubule cells in vitro.
Cieslinski, DA; Humes, HD; Messana, JM; Nguyen, VD, 1988
)
0.27
"Nephrotoxicity of radio-opaque contrast media (CM) is generally believed to involve toxic injury of proximal tubular cells."( Nephrotoxicity of high- and low-osmolality contrast media.
Avila, A; Dennis, B; Finnie, KJ; Jevnikar, AM; Linton, AL; Plummer, DT, 1988
)
0.27
" It is safe in humans, producing transient electrocardiographic and hemodynamic alterations that are less pronounced than those seen during routine coronary angiography."( Myocardial contrast echocardiography in humans: I. Safety--a comparison with routine coronary arteriography.
Kaul, S; Moore, CA; Smucker, ML, 1986
)
0.27
" These results demonstrate that the radiocontrast agent, diatrizoate, is directly toxic to renal proximal tubule cells."( Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells.
Humes, HD; Hunt, DA; White, MD, 1987
)
0.27
" Adverse effects of contrast media on kidney function include diuresis, changes in renal blood flow, osmotic nephroses, albuminuria, enzymuria and, most important, glomerular filtration rate."( Contrast media-induced nephrotoxicity. Survey and present state.
Almén, T; Golman, K,
)
0.13
" Adverse effects with arteriography include seizures, transient cortical blindness, brain edema, and spinal cord injury."( Neurotoxicity of radiological contrast agents.
Junck, L; Marshall, WH, 1983
)
0.27
" There was no difference in adverse side effects."( A double-blind clinical study comparing the safety and efficacy of Hexabrix and Renografin-76 in contrast enhanced computed body tomography.
DiSantis, DJ; James, M; Lee, JK; McClennan, BL,
)
0.13
"In several series of experiments with intracardiac application in anaesthetized dogs, the following contrast media were tested for their adverse effects on excitation and conduction of electrical activity in the heart."( Contrast media-induced side effects on excitation and conduction of electrical activity in the heart on intracardiac application. Investigations in anaesthetized dogs.
Diletti, E; Felix, R; Hahn, N; Logemann, N; Mählmann, J; Pantenburg, R; Potthoff, E; Raqué, B; Schmidt, I; Schuppert, J; Siering, T; Steinijans, V; Stiemert, D, 1981
)
0.26
" The intravenous biliary contrast medium--ioglycamate--was most toxic to all cell types."( Toxicity of X-ray contrast media in cell cultures.
Frey, H; Kormano, M,
)
0.13
"The purpose of this study was to determine if the selective use of low-osmolality contrast material for excretory urography and CT is safe and if it saves money."( Selective use of low-osmolality contrast agents for i.v. urography and CT: safety and effect on cost.
Duval, JF; Dye, J; Hunter, TB, 1994
)
0.29
" In conclusion, 1) amiodarone had a cytotoxic effect in CHO fibroblasts, a nonthyroid cell line; 2) this cytotoxic effect occurred in thyroid cells independent of their ability to organify iodide; 3) however, the toxic effect of amiodarone was greater and occurred at a lower molar concentration in freshly prepared human thyroid follicles that trap and organify iodide; and 4) in the latter culture system, methimazole, an inhibitor of iodide organification, partially, but significantly, reduced the cytotoxic effect of amiodarone."( Studies on the in vitro cytotoxic effect of amiodarone.
Braverman, LE; Chiovato, L; Lapi, P; Mammoli, C; Martino, E; Pinchera, A; Santini, F; Tonacchera, M, 1994
)
0.29
"During 73 single contrast investigations with 76% triobrast, 76% verographin, 76% urographin, urotrast and omnipaque-300, 65% of patients had clinical adverse reactions which were mainly mild."( [A mathematical analysis of the relationship of the clinical manifestations of side effects to the blood biochemical indices in subjects undergoing x-ray contrast studies].
Krivenko, EV; Markina, EV; Napolov, IuK; Napolova, EIu; Shimanovskaia, LS; Shimanovskiĭ, NL; Sviridov, NK,
)
0.13
"The radiocontrast agents reduced cell viability to a greater extent than hyperosmolal mannitol solutions in both cell lines; diatrizoate was more toxic than iopamidol."( Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers.
Haller, C; Kübler, W; Schick, CS; Zorn, M, 1997
)
0.3
"Diatrizoate is more toxic than iopamidol, which is partly related to its higher osmolality."( Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers.
Haller, C; Kübler, W; Schick, CS; Zorn, M, 1997
)
0.3
" No adverse events were observed among the children below 1 year of age."( Iopentol (Imagopaque 300) compared with iohexol (Omnipaque 300) and diatrizoate (Urografin 292) in pediatric urography. A clinical trial assessing adverse events and diagnostic information.
Brekke, O; Lanning, P, 1997
)
0.3
" Safety was assessed by monitoring serum pancreatic iso-amylase and by recording adverse events."( Iopentol (Imagopaque 250) compared with diatrizoate (Urografin 219) in endoscopic retrograde cholangio-pancreatography (ERCP). A clinical trial assessing safety (adverse events and S-pancreatic iso-amylase) and diagnostic information (VAS).
Bjartveit, K; Brock, A; Kruse, A; Nowakowska-Duawa, E; Rodenberg, J, 1997
)
0.3
" Safety was evaluated by assessing the numbers of patients reporting immediate adverse events (up to 30 min after injection) and delayed adverse events (within 7 days after the examination)."( Iopentol (Imagopaque 350) compared with diatrizoate (Urografin 370) in cerebral CT. A clinical trial assessing immediate and late (7 days) adverse events and diagnostic information (visualization quality and Hounsfield unit measurements).
Jakobsen, JA; Klaveness, AJ; Valentine, A, 1997
)
0.3
" With regards to cell viability, transmonolayer resistance and inulin permeability the radiocontrast agents with reduced osmolality were significantly less toxic than diatrizoate, independent of their ionic strength."( Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro.
Haller, C; Schick, CS, 1999
)
0.3
"In five dogs with normal renal function, doses of 200, 400, 600 and 800 mg of iodine/kg bodyweight of iohexol (350 mg of iodine/ml) were assessed in comparison to a dose of 880 mg of iodine/kg bodyweight of meglumine-sodium amidotrizoate (370 mg of iodine/ml) to determine the hematologic and biochemical parameters, urinalysis and urinary osmolality, pulse and respiratory rates, and adverse effects were determined."( [The adverse effects of the water-soluble iodinated contrast media used in excretory urography in the canine species].
Agut Giménez, A; Hita Rosino, E; Sánchez-Valverde García, MA, 1999
)
0.3
" These data indicate that DA and IA are toxic to renal cortical slices, and this is a more sensitive model than previously used cell culture systems."( Characterization of a novel model for investigation of radiocontrast nephrotoxicity.
Ball, JG; Duffy, SP; Harmon, RC; Terneus, MV; Valentovic, MA, 2009
)
0.35
" LOCM was less toxic to rat kidneys than HOCM."( The protective role of telmisartan against nephrotoxicity induced by X-ray contrast media in rat model.
Duan, SB; Liu, FY; Peng, YM; Wang, P; Wang, YH; Xu, XQ; Zou, Q, 2009
)
0.35
" The pathophysiology of CIN is not well understood, but direct toxic effects on renal cells have been postulated as contributing to CIN."( Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract.
Andreucci, M; De Sarro, G; Faga, T; Mattivi, F; Michael, A; Navarra, M; Pisani, A; Russo, D; Sabbatini, M, 2015
)
0.42
" Direct toxic effects on renal cells, possibly mediated by reactive oxygen species, have been postulated as contributing to CI-AKI."( Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells.
Andreucci, M; De Sarro, G; Faga, T; Michael, A; Pisani, A; Russo, D; Serra, R, 2018
)
0.48
" However, little information was available about whether ICM-derived DBPs are toxic to aquatic organisms."( Disinfection byproducts of iopamidol, iohexol, diatrizoate and their distinct acute toxicity on Scenedesmus sp., Daphnia magna and Danio rerio.
Liu, H; Watson, P; Yang, F; Yang, X; Zhou, N, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The method was used to determine pharmacokinetic parameters of iosulamide after intravenous administration to rhesus monkeys."( Analysis of iosulamide in plasma and urine: application to intravenous pharmacokinetics in rhesus monkey.
Biddlecome, CE; Edelson, J; Kullberg, MP; Park, GB; Rowe, EA,
)
0.13
" Some computed tomographic (CT) implications of these pharmacokinetic studies are discussed."( Pharmacokinetics of contrast media: experimental results in dog and man with CT implications.
Berger, N; Gardeur, D; Lautrou, J; Metzger, J; Millard, JC, 1980
)
0.26
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"To establish a pharmacokinetic model for the model drug, sodium diatrizoate (DTZ), allowing joint disappearance kinetics to be estimated from serum appearance kinetics following intra-articular administration, and to calculate the relative joint exposure after intravenous and intra-articular DTZ administration (F(iv/IA))."( The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse.
Andersen, PH; Frost, AB; Larsen, C; Larsen, F; Larsen, SW; Stürup, S; Thomsen, MH; Østergaard, J, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
"Subtotal resection of the head of the pancreas combined with duct obliteration of the distal pancreas by prolamine was performed in 12 selected patients who had chronic alcohol-induced pancreatitis with most destruction in the proximal pancreas."( Subtotal resection of the head of the pancreas combined with ductal obliteration of the distal pancreas in chronic pancreatitis.
De Groote, J; Fevery, J; Kerremans, RP; Penninckx, FM, 1987
)
0.27
" In a prospective study upon 247 patients with the possible diagnosis of acute diverticulitis ultrasound is a screening method with a high specificity (97 %) and leads in combination with the hydrocolonsonography and the colour flow doppler to a high sensitivity (76 %)."( [Which imaging in case of sigmoid diverticulitis? The value of ultrasound (Conventional B-mode in combination with hydrocolonsonography and colour flow Doppler) in comparison to the well-established modalities like contrast enema and helical computertomog
Mittelkötter, U; Moll, R; Reith, HB; Schindler, G; Thiede, A, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Since the latter is influenced by dosage and kind of application from this result immediate practical consequences for the excretion urography, for which at present a large dose and the bolus injection are preferred."( [Studies and computer analyses on the kinetics of nephrotropic contrast media in patients with different kidney function].
Baars, HG; Rauchfuss, J; Schabel, J; Weiss, M, 1978
)
0.26
" If the results of a repeat dosage oral cholecystogram are abnormal, the gallbladder probably is diseased, even if the results of an infusion tomographic examination of the gallbladder are normal."( Rapid roentgenologic diagnosis of acute cholecystitis.
Danley, RB; Love, L; Pickleman, JR, 1976
)
0.26
" Differences in diatrizoate concentration which existed between cortical and medullary zones in healthy kidneys at low dises were progressively eliminated as dosage increased, consistent with the osmatic fiutryiv rggrvy of diatrizoate."( Effect of dose on renal diatrizoate concentrations in experimental acute renal failure.
Gaunt, A; McLachlan, MS; Robinson, PJ, 1976
)
0.26
" We conclude that image quality in nonselective, intra-arterial DSA can be improved without an increase in iodine dosage by the rapid administration of undiluted contrast material in small volumes."( Nonselective digital subtraction angiography. Compact contrast material bolus for improved image quality.
Alvarado, R; Palmaz, JC; Rees, CR; Reuter, SR, 1989
)
0.28
" Dosage was adjusted for patient weight, and up to 150-ml of Hexabrix or Renografin-76 were injected over a 2-minute period during which rapid sequence CT was performed."( Double-blind comparison of Hexabrix and Renografin-76 in computed tomography.
Berland, LL,
)
0.13
" The beta 1,2 antagonist employed in the test decreased the contrast dosage by 13 per cent, causing the LD50."( Diazepam, alpha and beta neurotransmission modifying drugs and contrast media mortality in mice.
Johansson, G; Luostarinen, M; Virkkunen, P, 1984
)
0.27
"The dose-response relation of contrast medium-induced hyperemic response in coronary blood flow (contrast hyperemia) was investigated to determine the optimal dose of contrast medium (CM, Urografin-76) for the assessment of coronary flow reserve in man."( Validity of contrast hyperemia for clinical assessment of coronary flow reserve: the optimal dose of contrast medium and reproducibility of the technique.
Abe, H; Hori, M; Inoue, M; Kodama, K; Kuzuya, T; Mishima, M; Nanto, S; Tsujioka, K, 1983
)
0.27
"The effect of diatrizoate (Urografin325) on the cumulative dose-response curve of the vasodilatory response to acetylcholine was studied in the isolated perfused rat kidney (IPRK)."( Effect of radiographic contrast media on endothelium derived nitric oxide-dependent renal vasodilatation.
Haylor, J; Morcos, SK; Oldroyd, S, 1997
)
0.3
" Dose-response (0."( Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates.
Bacon, ER; Cooper, ER; Gazelle, GS; Haley, PJ; McIntire, GL; Toner, JL; Wolf, GL, 1994
)
0.29
" This study describes methods to obtain citrated whole blood and plasma from the zebrafish, analyze in vitro coagulation in small plasma volumes, obtain uniform dosing of zebrafish with oral anticoagulants, and demonstrate specific factor activities via chromogenic assays."( Analysis of blood coagulation in the zebrafish.
Jagadeeswaran, P; Sheehan, JP,
)
0.13
" CT scan utilizing a fixed dosage of orally administered water-soluble contrast containing diatrizoate salts, with a mean transit time of 50 min, provides a rapid and efficient means of visualizing the appendix in the clinical exclusion of appendicitis in the emergency setting."( Rapid CT scan visualization of the appendix and early acute non-perforated appendicitis using an improved oral contrast method.
Giuliano, C; Giuliano, V; Pinto, F; Scaglione, M, 2004
)
0.32
"The purpose of this study is to determine if focused CT examinations of the pelvis, utilizing fixed oral dosage of diatrizoate contrast media, improve overall reader confidence in visualization of the appendix."( CT method for visualization of the appendix using a fixed oral dosage of diatrizoate--clinical experience in 525 cases.
Giuliano, C; Giuliano, V; Pinto, F; Scaglione, M, 2005
)
0.33
"Five hundred and twenty-five patients referred for, rule out appendicitis, evaluations underwent focused CT examinations of the pelvis following fixed oral dosage of diatrizoate contrast media."( CT method for visualization of the appendix using a fixed oral dosage of diatrizoate--clinical experience in 525 cases.
Giuliano, C; Giuliano, V; Pinto, F; Scaglione, M, 2005
)
0.33
" Enhanced supine CT images following oral administration of fixed dosage of diatrizoate had consistently good scores for reader confidence for bowel opacification (4."( CT method for visualization of the appendix using a fixed oral dosage of diatrizoate--clinical experience in 525 cases.
Giuliano, C; Giuliano, V; Pinto, F; Scaglione, M, 2005
)
0.33
"The use of fixed oral dosage of diatrizoate contrast media resulted in good overall reader confidence to visualize the appendix and peri-appendiceal area, in addition to high specificity and rapid transit time."( CT method for visualization of the appendix using a fixed oral dosage of diatrizoate--clinical experience in 525 cases.
Giuliano, C; Giuliano, V; Pinto, F; Scaglione, M, 2005
)
0.33
" With the blood pool agent, similar contrast enhancement to the conventional agent was achieved with about 36% reduced dosage of iodine per body weight (mg I/kg)."( Comparison of liver perfusion parameters studied with conventional extravascular and experimental intravascular CT contrast agents.
Häkkinen, AM; Halavaara, J; Kapanen, M, 2007
)
0.34
" Randomized clinical trials focused on OK-432, bleomycin, or alcoholic solution of zein; standardized dosing protocols; and consistent and reliable outcome reporting will be necessary for further development of treatment guidelines."( Sclerotherapy for lymphatic malformations in children: a scoping review.
Ali, A; Churchill, P; Flageole, H; Otal, D; Pemberton, J; Walton, JM, 2011
)
0.37
" The proposed methods have been successfully applied to the analysis of DTA in pharmaceutical dosage forms without interference from other dosage form additives."( Stability indicating spectrophotometric and spectrodensitometric methods for the determination of diatrizoate sodium in presence of its degradation product.
Abd El-Rahman, MK; Abdel Gawad, SA; Fawaz, EM; Riad, SM; Shehata, MA, 2015
)
0.42
" The proposed methods have been successfully applied to the analysis of DTA in pharmaceutical dosage forms without interference from other dosage form additives."( A comparative study between three stability indicating spectrophotometric methods for the determination of diatrizoate sodium in presence of its cytotoxic degradation product based on two-wavelength selection.
El-Rahman, MKA; Fawaz, EM; Riad, SM; Shehata, MA, 2015
)
0.42
" First, the effect of H2O2 dosage on mineralization efficiency was determined using ultraviolet (UV) irradiation."( Elimination of radiocontrast agent diatrizoic acid by photo-Fenton process and enhanced treatment by coupling with electro-Fenton process.
Bocos, E; Oturan, MA; Oturan, N; Pazos, M; Sanromán, MÁ, 2016
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,840)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902249 (79.19)18.7374
1990's367 (12.92)18.2507
2000's118 (4.15)29.6817
2010's95 (3.35)24.3611
2020's11 (0.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.68 (24.57)
Research Supply Index8.16 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index42.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials198 (6.03%)5.53%
Reviews59 (1.80%)6.00%
Case Studies249 (7.58%)4.05%
Observational0 (0.00%)0.25%
Other2,777 (84.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]